J.Jill (JILL) Buy Rating Reiterated by Analysts at Deutsche Bank; The TP Given is $5; Glenview Capital Management Cut By $67.66 Million Its Abbvie (ABBV) Position

March 19, 2018 - By Dolores Ford

Glenview Capital Management Llc decreased Abbvie Inc (ABBV) stake by 12.58% reported in 2017Q3 SEC filing. Glenview Capital Management Llc sold 768,838 shares as Abbvie Inc (ABBV)’s stock rose 6.17%. The Glenview Capital Management Llc holds 5.34 million shares with $474.63 million value, down from 6.11M last quarter. Abbvie Inc now has $178.82 billion valuation. The stock decreased 0.97% or $1.1 during the last trading session, reaching $112.61. About 2.44M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since March 19, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 5 analysts covering JJill Inc (JILL), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. JJill Inc has $10.0 highest and $5.0 lowest target. $7.20’s average target is 66.28% above currents $4.33 stock price. JJill Inc had 7 analyst reports since December 5, 2017 according to SRatingsIntel. The rating was maintained by Morgan Stanley on Friday, March 16 with “Equal-Weight”. On Thursday, March 15 the stock rating was maintained by SunTrust with “Hold”. Jefferies maintained the shares of JILL in report on Thursday, March 15 with “Buy” rating. The rating was maintained by Cowen & Co with “Buy” on Thursday, March 15. The company was maintained on Tuesday, December 5 by RBC Capital Markets. The rating was maintained by SunTrust on Friday, February 2 with “Hold”. The firm earned “Hold” rating on Friday, March 16 by RBC Capital Markets.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 79 analyst reports since July 21, 2015 according to SRatingsIntel. As per Tuesday, February 23, the company rating was upgraded by Citigroup. The stock has “Hold” rating by Cowen & Co on Tuesday, September 5. Cowen & Co downgraded the stock to “Market Perform” rating in Monday, June 6 report. Jefferies maintained AbbVie Inc. (NYSE:ABBV) rating on Monday, June 26. Jefferies has “Buy” rating and $9000 target. The firm has “Buy” rating given on Wednesday, July 22 by SunTrust. The stock of AbbVie Inc. (NYSE:ABBV) earned “Hold” rating by BMO Capital Markets on Wednesday, April 19. Credit Suisse maintained it with “Hold” rating and $135.0 target in Monday, January 29 report. The rating was downgraded by UBS on Monday, September 25 to “Neutral”. The firm has “Equal-Weight” rating by Barclays Capital given on Friday, October 13. The firm earned “Buy” rating on Monday, March 7 by Goldman Sachs.

Investors sentiment decreased to 0.8 in Q3 2017. Its down 0.05, from 0.85 in 2017Q2. It fall, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Capital Inv Advsr Ltd Liability Com reported 0.2% stake. Wilbanks Smith & Thomas Asset Mgmt Ltd Liability Corp holds 0.18% or 24,610 shares in its portfolio. Drexel Morgan & holds 5,300 shares. Brown Advisory Secs Limited Liability Co reported 0.92% stake. Park National Corporation Oh has 290,783 shares for 1.48% of their portfolio. Grand Jean Mgmt Inc owns 11,165 shares. Rice Hall James And Assoc Ltd accumulated 15,837 shares. California-based Destination Wealth Mgmt has invested 2% in AbbVie Inc. (NYSE:ABBV). Oakbrook Ltd Liability invested in 27,957 shares. Leavell Invest Mgmt Inc, a Alabama-based fund reported 68,206 shares. State Farm Mutual Automobile Ins holds 15.06 million shares or 1.79% of its portfolio. Sageworth Trust Communication invested in 111,937 shares or 1.87% of the stock. Forte Ltd Liability Co Adv has invested 0.42% in AbbVie Inc. (NYSE:ABBV). Walter Keenan Financial Consulting Mi Adv invested in 35,016 shares. M&R Capital Mgmt Incorporated has 26,749 shares for 0.57% of their portfolio.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on April, 26. They expect $1.78 EPS, up 39.06% or $0.50 from last year’s $1.28 per share. ABBV’s profit will be $2.83 billion for 15.82 P/E if the $1.78 EPS becomes a reality. After $1.48 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 20.27% EPS growth.

Glenview Capital Management Llc increased Flex Ltd (NASDAQ:FLEX) stake by 1.27 million shares to 39.43 million valued at $653.40M in 2017Q3. It also upped Laboratory Corp Amer Hldgs (NYSE:LH) stake by 243,200 shares and now owns 2.91 million shares. Mckesson Corp (NYSE:MCK) was raised too.

Since September 28, 2017, it had 0 insider purchases, and 13 sales for $49.94 million activity. The insider Gosebruch Henry O sold $1.66 million. On Wednesday, February 28 RICHMOND TIMOTHY J. sold $2.15M worth of AbbVie Inc. (NYSE:ABBV) or 18,129 shares. Another trade for 83,574 shares valued at $9.57 million was sold by ALBAN CARLOS. SEVERINO MICHAEL sold $311,684 worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28. 6,699 shares valued at $589,512 were sold by Michael Robert A. on Thursday, September 28. The insider SALEKI-GERHARDT AZITA sold 1,337 shares worth $157,458. 25,000 shares were sold by Schumacher Laura J, worth $2.95 million on Wednesday, February 28.

J.Jill, Inc. operates as a specialty retailer of women's apparel under the J.Jill brand in the United States. The company has market cap of $189.45 million. It offers knit and woven tops, bottoms, and dresses, as well as sweaters and outerwear; and complementary footwear and accessories, including scarves, jewelry, and hosiery for misses, petite, and women. It has a 3.41 P/E ratio. The Company’s clients include women in 40-65 age range.

The stock decreased 2.70% or $0.12 during the last trading session, reaching $4.33. About 632,301 shares traded or 25.08% up from the average. J.Jill, Inc. (JILL) has 0.00% since March 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts